Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Main Street Group LTD

Main Street Group LTD lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 27.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 618 shares of the biopharmaceutical company’s stock after selling 232 shares during the quarter. Main Street Group LTD’s holdings in Gilead Sciences were worth $57,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. FMR LLC lifted its position in shares of Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after acquiring an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock valued at $3,293,822,000 after purchasing an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock valued at $2,608,337,000 after purchasing an additional 749,047 shares during the period. Norges Bank purchased a new position in Gilead Sciences in the 4th quarter worth about $1,789,254,000. Finally, Northern Trust Corp grew its stake in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after acquiring an additional 2,458,954 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $19,977,938.37. This trade represents a 9.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 22,929 shares of company stock worth $2,644,895 in the last quarter. 0.27% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research analyst reports. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective on the stock. Oppenheimer cut their price objective on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, April 25th. Royal Bank of Canada boosted their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 25th. Finally, Bank of America upped their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Stock Down 2.3%

Shares of NASDAQ:GILD opened at $101.43 on Wednesday. The company’s fifty day moving average is $106.71 and its 200-day moving average is $99.51. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a market capitalization of $126.30 billion, a PE ratio of 274.14, a P/E/G ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.32) EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 3.12%. Gilead Sciences’s payout ratio is presently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.